Nascent Biotech, Inc.
NBIO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $8 | $15 | $31 | $29 |
| - Cash | $0 | $0 | $0 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $8 | $15 | $30 | $28 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | -5,361,374.4% | – |
| EBITDA | -$0 | -$0 | -$1 | -$0 |
| % Margin | – | – | -15,182,908.8% | – |
| Net Income | -$0 | -$0 | -$1 | -$0 |
| % Margin | – | – | -15,195,497.6% | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.001 |
| % Growth | 31.8% | 26.7% | -150% | – |
| Operating Cash Flow | – | -$0 | -$0 | -$0 |
| Capital Expenditures | – | $0 | -$0 | $0 |
| Free Cash Flow | – | -$0 | -$0 | -$0 |